肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 欧洲实践建议：COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤患者的管理

2021-01-28 国外肿瘤科相关专家小组（统称） Eur J Cancer . 2021 Feb;144:200-214.

神经内分泌肿瘤

神经内分泌肿瘤（NENs）是一种不常见的异质性肿瘤，其诊断、临床治疗需要多学科协作的方法，本文主要针对COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤的多学科管理提供指导建议。

中文标题：

2021 欧洲实践建议：COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤患者的管理

英文标题：

Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2021-01-28

简要介绍：

神经内分泌肿瘤（NENs）是一种不常见的异质性肿瘤，其诊断、临床治疗需要多学科协作的方法，本文主要针对COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤的多学科管理提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 欧洲实践建议：COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤患者的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ed8201c0020ae179, title=2021 欧洲实践建议：COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤患者的管理, enTitle=Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era, guiderFrom=Eur J Cancer . 2021 Feb;144:200-214., authorId=0, author=, summary=神经内分泌肿瘤（NENs）是一种不常见的异质性肿瘤，其诊断、临床治疗需要多学科协作的方法，本文主要针对COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤的多学科管理提供指导建议。, cover=https://img.medsci.cn/2021131/1612083438321_2020535.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Jan 28 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>神经内分泌肿瘤（NENs）是一种不常见的异质性肿瘤，其诊断、临床治疗需要多学科协作的方法，本文主要针对COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤的多学科管理提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=747, tagName=神经内分泌肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=747, guiderKeyword=神经内分泌肿瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2464, appHits=217, showAppHits=0, pcHits=311, showPcHits=2247, likes=3, shares=75, comments=7, approvalStatus=1, publishedTime=Sun Jan 31 17:51:13 CST 2021, publishedTimeString=2021-01-28, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Jan 31 16:57:24 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 11:31:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 欧洲实践建议：COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤患者的管理.pdf)])
2021 欧洲实践建议：COVID-19流行时期胃肠胰和胸部（类癌）神经内分泌肿瘤患者的管理.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1076181, encodeId=633110e6181a9, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92de6160036, createdName=ms5000000263087736, createdTime=Thu Dec 02 11:58:51 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008683, encodeId=089b100868337, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:31 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922041, encodeId=8ea39220410c, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:07:23 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922040, encodeId=eb0d92204087, content=好指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:06:51 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-12-02 ms5000000263087736

    很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1076181, encodeId=633110e6181a9, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92de6160036, createdName=ms5000000263087736, createdTime=Thu Dec 02 11:58:51 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008683, encodeId=089b100868337, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:31 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922041, encodeId=8ea39220410c, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:07:23 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922040, encodeId=eb0d92204087, content=好指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:06:51 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-08-17 ms1000001256854968

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1076181, encodeId=633110e6181a9, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92de6160036, createdName=ms5000000263087736, createdTime=Thu Dec 02 11:58:51 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008683, encodeId=089b100868337, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:31 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922041, encodeId=8ea39220410c, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:07:23 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922040, encodeId=eb0d92204087, content=好指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:06:51 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-02-01 ms1000002016287811

    好好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1076181, encodeId=633110e6181a9, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92de6160036, createdName=ms5000000263087736, createdTime=Thu Dec 02 11:58:51 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008683, encodeId=089b100868337, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 13:59:31 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922041, encodeId=8ea39220410c, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:07:23 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922040, encodeId=eb0d92204087, content=好指南, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Mon Feb 01 21:06:51 CST 2021, time=2021-02-01, status=1, ipAttribution=)]
    2021-02-01 ms1000002016287811

    好指南

    0

相关指南

2018 IARC/WHO专家共识：神经内分泌肿瘤常用分类方法

世界卫生组织(WHO,The World Health Organization) · 2018-08-23

2017 ENETS共识指南：神经内分泌肿瘤的生物标志物

欧洲神经内分泌肿瘤学会(ENETS,European Neuroendocrine Tumor Society) · 2017-04-08

2017 ENETS共识建议：神经内分泌肿瘤的随访和记录

欧洲神经内分泌肿瘤学会(ENETS,European Neuroendocrine Tumor Society) · 2017-02-17

拓展阅读

2016 ENETS共识指南：空肠和回肠神经内分泌肿瘤（更新版）

欧洲神经内分泌肿瘤学会(ENETS,European Neuroendocrine Tumor Society) · 2016-01-12

2017 ENETS共识建议：神经内分泌肿瘤的随访和记录

欧洲神经内分泌肿瘤学会(ENETS,European Neuroendocrine Tumor Society) · 2017-02-17

2017 ENETS共识指南：神经内分泌肿瘤的生物标志物

欧洲神经内分泌肿瘤学会(ENETS,European Neuroendocrine Tumor Society) · 2017-04-08

2018 IARC/WHO专家共识：神经内分泌肿瘤常用分类方法

世界卫生组织(WHO,The World Health Organization) · 2018-08-23

胃肠胰神经内分泌肿瘤诊治专家共识（2020·广州）

中华医学会消化病学分会(CSGE,Chinese Society Of Gastroenterology) · 2021-02-10

中国抗癌协会神经内分泌肿瘤诊治指南（2022年版）

中国抗癌协会神经内分泌肿瘤专业委员会 · 2022-06-30